Skip to main content
. 2014 Mar 13;9:74. doi: 10.1186/1748-717X-9-74

Table 1.

Patient Characteristics

Parameter Total (%) Symptomatic a N (%) p-value
No of patients
100 (100)
59 (59)
 
Gender
 
 
0.65
Male/Female
60(60)/40(40)
35(58.3)/26(65)
Age
 
 
0.011
Symptomatic (IQR)
 
59.5-73 yrs
Asymptomatic (IQR)
54-66 yrs
Stageb
 
 
0.36
I
6 (6)
1 (16.7)
II
5 (5)
4 (80)
III
78 (78)
48 (61.5)
IV
11 (11)
6 (54.5)
Tumor locationb
 
 
0.97
LLL
15 (15)
10 (66.7)
LUL
25 (25)
15 (60)
RLL
9 (9)
6 (66.7)
RML
6 (6)
4 (66.7)
RUL
45 (45)
24 (53.3)
Tumor histologyb
 
 
0.66
Adenocarcinoma
57 (57)
30 (52.6)
Neuroendocrine
1 (1)
1 (100)
Non-small
18 (18)
13 (72.2)
Squamous
24 (24)
15 (62.5)
Treatment typeb
 
 
0.89
IMRT
64 (64)
35 (54.7)
Proton
13 (13)
9 (69.2)
3D Conformal
23 (23)
15 (65.2)
Chemotherapy status
 
 
0.66
Concurrent
86 (86)
52 (60.5)
RT alone
14 (14)
7 (50)
Smoking historyb
 
 
0.92
Currently
28 (28)
15 (53.6)
Former
66 (66)
40 (60.6)
Never
6 (6)
4 (66.7)
Interval between staging PET/CT and start of RT
0.65
Median (range) in days 18 (3–69) 15 (3–69)

aSymptomatic status: CTCAEv4 RP grade ≥ 2.

bYates’ continuity correction applied.

IQR: Inter-quartile range.

Note: Hypothesis testing for association used the Mann–Whitney U test for continuous predictors; Pearson’s chi-squared test for marginal homogeneity for categorical predictors.